Bristol buying out Axion stake in Oncology Therapeutics Network joint venture.
Executive Summary
BRISTOL TO BUY OUT ONCOLOGY THERAPEUTICS NETWORK JOINT VENTURE from co-owner Axion, a San Bruno, Calif.-based oncology specialty firm, BMS announced Aug. 5. Bristol-Myers Squibb bought a 50% interest in Oncology Therapeutics Network in 1993. Axion founded its physician-office oncology product distribution business in 1990.